Explore the words cloud of the XHaLe project. It provides you a very rough idea of what is the project "XHaLe" about.
The following table provides information about the project.
MEDIZINISCHE HOCHSCHULE HANNOVER
|Coordinator Country||Germany [DE]|
|Total cost||1˙989˙250 €|
|EC max contribution||1˙989˙250 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2018-06-01 to 2023-05-31|
Take a look of project's partnership.
|1||MEDIZINISCHE HOCHSCHULE HANNOVER||DE (HANNOVER)||coordinator||1˙989˙250.00|
Non-neoplastic lung diseases (NNLD), such as COPD and interstitial lung diseases rank second among the causes of death and NNLD appear as a growing EU wide challenge. They are characterized by irreversible remodeling with a relentless loss of lung function and a 5-year survival of only 30%. This dysfunctional reaction to injury can be triggered by particulate matters with macrophages (MO) as the key regulators. Wholesale therapeutic suppression of the inflammome actually increases the risk of death, whereas targeted therapy of signalling cascades by novel pharmaceuticals, e.g. nintedanib, only slows disease progression. Thus lung transplantation remains the ultima ratio. However, available grafts are limited, treatment costs are high and the 5-year survival barely surpasses 50%. Therefore novel approaches to understand, prevent and ultimately cure NNLDs are urgently needed. Towards this goal my group focusses on both, the main effector cell in NNLD, the myofibroblast, and the inflammome and particularly MOs, as these orchestrate both, lung healing and remodeling. Modulating the pulmonary immune system, rather than subduing it, holds significant promise. To this end, we have to understand the very early events in NNLDs. There are 2 major obstacles for efficient research: i) the lack of adequate animal models and ii) the availability of human specimens. Therefore we established a unique platform for NNLD: we utilize fresh explanted human lungs from Europe’s largest LuTx program and set up a singular 24h/7d workflow, ensuring short ischemia and tissue viability. In the last years, we have worked up over 500 lungs, acted as an international multiplier for pulmonary research, patented new imaging techniques and described novel diseases. Our understanding MO biology in NNLDs showed us the great potential in macrophages. Now we are going to use these macrophages as potential therapeutics. Hereby we will make a difference in translational medicine in Europe and the world.
|year||authors and title||journal||last update|
F. LÃ¤nger, H. Stark, P. Braubach, M. Ackermann, K. Hussein, K. Teiken, L. Maegel, M. Kuehnel, D. Jonigk
SchÃ¤digungsmuster interstitieller Lungenerkrankungen
published pages: 262-271, ISSN: 0172-8113, DOI: 10.1007/s00292-018-0503-1
|Der Pathologe 39/S2||2020-02-05|
J. Wohlschlaeger, F. Laenger, J. Gottlieb, T. Hager, A. Seidel, D. Jonigk
published pages: 281-291, ISSN: 0172-8113, DOI: 10.1007/s00292-019-0598-z
|Der Pathologe 40/3||2020-02-05|
Maximilian Ackermann, Helge Stark, Lavinia Neubert, Stephanie Schubert, Paul Borchert, Friedemann Linz, Willi L. Wagner, Wolfram Stiller, Mark WielpÃ¼tz, Anne Hoefer, Axel Haverich, Steven J. Mentzer, Harshit R. Shah, Tobias Welte, Mark Kuehnel, Danny Jonigk
Morphomolecular motifs of pulmonary neoangiogenesis in interstitial lung diseases
published pages: 1900933, ISSN: 0903-1936, DOI: 10.1183/13993003.00933-2019
|European Respiratory Journal||2020-01-30|
Danny Jonigk, Helge Stark, Peter Braubach, Lavinia Neubert, Hoenâ€oh Shin, Nicole Izykowski, Tobias Welte, Sabina Janciauskiene, Gregor Warnecke, Axel Haverich, Mark Kuehnel, Florian Laenger
Morphological and molecular motifs of fibrosing pulmonary injury patterns
published pages: 256-271, ISSN: 2056-4538, DOI: 10.1002/cjp2.141
|The Journal of Pathology: Clinical Research 5/4||2020-01-30|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "XHALE" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "XHALE" are provided by the European Opendata Portal: CORDIS opendata.